PharmaCyte Biotech, Inc. reported no revenue for the fiscal years ending April 30, 2026, and 2025, continuing its trend of operating at a loss. The company recorded a net loss attributable to common stockholders of approximately $23 million for the year ended April 30, 2026, a significant decrease from a net income of about $23 million in the previous fiscal year. This shift is largely attributed to a $1.5 million impairment of an intangible asset and increased operating expenses, which rose to approximately $6.9 million, up from $4.4 million in 2025. The increase in operating expenses was driven by higher compensation costs, director fees, and legal and professional expenses.
The company has faced significant challenges, including a clinical hold placed by the U.S. Food and Drug Administration (FDA) on its Investigational New Drug (IND) application for a planned clinical trial in locally advanced pancreatic cancer (LAPC). The hold has been in effect since October 2020, and PharmaCyte has been working to address the FDA's requests for additional data and studies. The company has formed a Strategic Scientific Committee to review its development programs and its relationship with SG Austria Pte. Ltd., which has raised concerns regarding the expiration of licensed patents and the dependency on SG Austria for its proprietary Cell-in-a-Box® technology.
PharmaCyte's operational metrics indicate a reliance on third-party manufacturers, particularly Austrianova, for the production of its product candidates. The company has reported supply chain disruptions and liquidity issues with Austrianova, which could impact its ability to manufacture products for clinical trials and future commercialization. As of April 30, 2026, PharmaCyte had two full-time employees and several consultants, reflecting a lean operational structure as it navigates its development pipeline.
Looking ahead, PharmaCyte's future remains uncertain as it seeks to lift the clinical hold and secure necessary funding for its operations. The company has approximately $18.6 million in cash and cash equivalents, which it believes will sustain its operations for at least the next 12 months. However, the ongoing challenges related to regulatory approvals, reliance on third-party manufacturers, and the need for additional capital raise significant risks to its business model and long-term viability. The company is also subject to various market risks, including fluctuations in stock price and potential delisting from Nasdaq due to non-compliance with listing requirements.
About PharmaCyte Biotech, Inc.
PharmaCyte Biotech develops cellular therapies for cancer using proprietary live cell encapsulation technology, Cell-in-a-Box. Its focus includes treatments for pancreatic tumors, leveraging genetically engineered cells to activate prodrugs at tumor sites. The company aims to address unmet medical needs with targeted, minimally immunogenic therapies, operating within the biotech and cancer treatment markets, with a strong emphasis on regulatory compliance and intellectual property protection.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov